Cases & Deals

  • Home
  • Practices
  • Pharnext completes €30.9 million IPO on Alternext market of Euronext in Paris

Share

Pharnext completes €30.9 million IPO on Alternext market of Euronext in Paris

September 2016

Client(s) Pharnext SAS

Jones Day represented Pharnext SAS, a biopharmaceutical company that develops new treatments targeting simultaneously several pathological mechanisms in neurological diseases, in connection with the €30.9 million (US$34.4 million) initial public offering on the Alternext market of Euronext in Paris.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.